Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (127) clinical trials

Plaque psoriasis or just, psoriasis, is a common skin disorder that presents as red scaly patches that can show up anywhere on the body. It is also common for these red patches to have white or silverly colored appearance. This study is researching the safety and effectiveness of a new ...

Phase

6.27 miles

Learn More »

Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of AM0010 in combination with Nivolumab versus Nivolumab alone in patients with stage IV / metastatic wild type Non-Small Cell Lung Cancer and tumors with low tumor expression of PD-L1 (0-49%)

Phase

6.27 miles

Learn More »

Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of AM0010 in combination with Pembrolizumab versus Pembrolizumab alone in patients with stage IV / metastatic wild type Non-Small Cell Lung Cancer and tumors with high expression of PD-L1 (> 50%)

Phase

6.27 miles

Learn More »

A Study of Biomarker-Directed Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with ...

Phase

6.27 miles

Learn More »

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

6.3 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis

Thirty-six (36) male or postmenopausal/surgically sterilized female subjects with IPF who are eligible, will be randomly enrolled in a 2:1 ratio (KD025 to SOC) to one of two treatment groups. Subjects randomized to Treatment Group 1 will receive KD025 400 mg QD orally for 24 weeks. Subjects randomized to Treatment ...

Phase

6.77 miles

Learn More »

Clinical Evaluation of 18F-AV-1451

This study is designed to expand the database of 18F-AV-1451 safety and tau binding as measured by PET imaging and to provide standardized conditions for 18F-AV-1451 use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.

Phase

6.77 miles

Learn More »

Emricasan a Caspase Inhibitor for Treatment of Subjects With Decompensated NASH Cirrhosis

The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48. All subjects will continue treatment until the last subject in the study reaches 48 weeks in the study. At least 30% of subjects ...

Phase

6.77 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

Phase

6.77 miles

Learn More »

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

This is a Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of balovaptan (RO5285119) in children and adolescents aged 5-17 years with ASD who are high functioning (intelligence quotient [IQ] greater than or equal to [>=] 70). Enrollment will be ...

Phase

6.77 miles

Learn More »